Chemokine CXCR4 receptor modulators and uses related thereto

The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. The receptor modulators can be formulated to form pharmaceutical compositions comprising the disclosed compounds or pharmaceutically acceptable salts or prodrugs thereof. The compositions 5 may be used for managing CXCR4 related conditions, typically prevention or treatment of viral

The Problem

As of the end of 2007, an estimated 33 million people worldwide were living with HIV/AIDS, and the Centers for Disease Control and Prevention (CDC) estimates that 1,200,000 U.S. residents are living with HIV infection (UNAIDS/WHO AIDS epidemic update, December 2008; The Henry J. Kaiser Family Foundation HIV/AIDS Policy Fact Sheet, July 2007). Although new infections have decreased in recent years, an estimated 2.6 million new HIV infections occurred worldwide during 2007 and approximately 40,000 new HIV infections occur each year in the United States. HIV entry within the target cells involves a series of molecular events. The three main steps of virus entry within the cell are: (i) attachment of the virus to the subject cells; (ii) interaction of the virus with the co-receptors; and (iii) fusion of the virus and subject cell membranes. Considering the complexity of the molecular events involved in viral infection, all three of these steps have been considered for drug design. The T-lymphocyte cell surface protein CD4 is the primary receptor involved in the interaction with the viral glycoprotein gp120, but a 11 26 Feb 2026 cellular co-receptor is also needed for the successful ent

In existing solutions, practitioners face limitations in achieving desired outcomes efficiently. This invention directly addresses these gaps by introducing novel technical approaches and mechanisms.

What This Invention Does

DETAILED DESCRIPTION Terms 20 For R substituents, the symbol indicates the carbon which forms the point of attachment to the H RB HN Markush structure. For example, in the Formula: wherein RB is NH , the , IZ H N NH HN proposed species is As used herein, “alkyl” means a noncyclic straight chain or branched, unsaturated or saturated hydrocarbon such as those containing from 1 to 10 carbon atoms, typically 1 to 4 otherwise designated C- 25 4alkyl. Representative saturated straight chain alkyls include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n- hexyl, n-septyl, n-octyl, n-nonyl, and the like; while saturated branched alkyls include isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, and the like.

The integration of these technical elements creates a system capable of delivering improved performance over existing alternatives. The inventors have identified and implemented solutions to key challenges that have limited previous approaches in this field.

Key Features

Innovative Technical Integration. The system seamlessly combines multiple functional components to work as a coordinated whole, enabling capabilities that would be difficult or impossible with standalone elements.

Dynamic Parameter Management. The invention includes mechanisms for adapting operational parameters based on conditions and requirements, allowing for optimized performance across diverse scenarios.

Enhanced Efficiency and Capability. Through its novel architecture and control mechanisms, the system achieves superior performance metrics compared to conventional approaches in the field.

Who Is Behind It?

Emory University has brought this innovation to the patent system with expertise from a skilled team of inventors: LIOTTA, Dennis C; JECS, Edgars; WILSON, Robert James; NGUYEN, Huy Hoang; KIM, Michelle Bora; WILSON, Lawrence; MILLER, Eric James; TAHIROVIC, Yesim Altas; TRUAX, Valarie. This represents their commitment to advancing technology in this important field.

Why It Matters

This patent application demonstrates significant innovation in an important technical area. The solutions described in the specification have the potential to improve how practitioners approach problems and deliver value in real-world applications.

The international patent classifications include A61K 31/4709 (2006.01) A61K 31/496 (2006.01) A61K 31/4725 (2006.01). These codes situate the invention within the broader landscape of technological innovation and represent important areas of advancement.

---

AU 2026201455 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.

Related Concepts

The CXCR4 receptor is a chemokine receptor found on T-lymphocytes that acts as a co-receptor for HIV-1 cellular entry alongside CD4. Blocking CXCR4-mediated entry is a validated therapeutic strategy in HIV/AIDS treatment. Entry inhibitors that target this pathway represent one of several classes of antiretroviral drugs and are also being investigated for potential roles in cancer, where CXCR4 signalling influences tumour cell migration and metastasis.